Cotargeting the mammalian target of rapamycin pathway and estrogen receptor may prevent or delay endocrine resistance in patients receiving first-line treatment for advanced breast cancer.
E ndocrine-based single-agent or combination therapy is the standard of care for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.
1 However, most responders to initial endocrine therapy eventually acquire resistance, experience relapse, and develop progressive disease. 2, 3 Dual inhibition of the mammalian target of rapamycin (mTOR) pathway and estrogen receptor can restore sensitivity to patients with endocrine therapy-resistant advanced breast cancer. 2, 4 Preclinical studies have also shown that early intervention with mTOR inhibitors plus endocrine therapy could delay or prevent endocrine resistance by preventing the emergence of hormoneindependent cells.
5
Everolimus is an oral, potent, selective mTOR inhibitor that acts synergistically with letrozole. 3, 6, 7 Phase 2 studies combining everolimus with endocrine therapy, such as tamoxifen (Tamoxifen Plus Everolimus [TAMRAD] study), letrozole, or fulvestrant (PrECOG 0102 study) reported improved efficacy vs endocrine therapy alone in postmenopausal women with HR+ breast cancer in the neoadjuvant and advanced settings. 4, 6, 8 In the phase 3 BOLERO-2 (Breast Cancer Trials of Oral Everolimus) trial, everolimus plus exemestane significantly improved median progression-free survival (PFS) vs placebo plus exemestane in women with HR+, HER2-advanced breast cancer progressing with nonsteroidal aromatase inhibitors (7.8 vs 3.2 months; hazard ratio [HR] , 0.45; 95% CI, 0.38-0.54), which led to the approval of everolimus plus exemestane in this setting. 3, 9 In an exploratory analysis of BOLERO-2, median PFS was also improved in patients receiving first-line treatment with everolimus plus exemestane following recurrence after adjuvant therapy (HR, 0.39; 95% CI, 0.25-0.62). 10 The consistent efficacy of everolimus in these studies supports the rationale for combining everolimus with endocrine therapy for first-line treatment of HR+ advanced breast cancer. Herein, we assess first-line treatment with everolimus plus letrozole in postmenopausal women with estrogen receptorpositive (ER+), HER2-advanced breast cancer. We also investigate continuing treatment with everolimus in combination with exemestane in patients whose disease progressed during everolimus plus letrozole therapy. is an open-label, multicenter, single-arm, phase 2 study conducted at 56 centers across 13 countries (eTable 1 in the Supplement). Eligible patients were postmenopausal women with ER+, HER2-advanced breast cancer. Patients were required to have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0, 11 or bone lesions (lytic or mixed). Eastern Cooperative Oncology Group performance status of 0 to 2 and adequate bone marrow, coagulation, liver, and renal function were also required. Prior neoadjuvant endocrine therapy was permitted, but therapy with nonsteroidal aromatase inhibitors must have been completed 1 or more years before enrollment. Patients who had received prior hormonal or other systemic therapy for advanced disease or prior treatment with (or known hypersensitivity to) an mTOR inhibitor were excluded. Further inclusion and exclusion criteria are presented in the eMethods in the Supplement. All patients provided written informed consent before enrollment. Study conduct adhered to Good Clinical Practice guidelines, local regulations, and the ethical principles of the Declaration of Helsinki, 12 and approval came from institutional review boards, independent ethics committees, and/or research ethics boards at each center (eAppendix in the Supplement). A steering committee supervised the study per the protocol.
Methods

Study Design and Participants
Procedures
Patients received first-line oral treatment with everolimus, 10 mg/d, and letrozole, 2.5 mg/d, until disease progression, unacceptable toxic effects, or withdrawal of consent.
Patients who discontinued treatment due to disease progression could then, at the investigator's discretion, receive second-line oral treatment with everolimus, 10 mg/d, and exemestane, 25 mg/d, until further disease progression, unacceptable toxic effects, or withdrawal of consent. Dose modifications were allowed and are described in the eMethods in the Supplement. Tumors were assessed by the investigators (M.R., T.B., C.V., M.Ö., S.J.A., F.M.C., R.H., T.T., C.F., J.J., V.S.) and/or designated radiologist per RECIST, version 1.0, using mainly computed tomography or magnetic resonance imaging at screening and every 8 weeks (±1 week) thereafter until the end of first-line treatment; assessments were also performed every 8 weeks in the second-line setting. A confirmation scan or photograph for measurable skin lesions was obtained at least 4 weeks after the initial observation of a response.
An exploratory, randomized substudy that assessed alcohol-free dexamethasone mouthwash vs the local standard of oral care for the treatment of symptomatic stomatitis among patients in the United States has been previously reported (eMethods in the Supplement).
Outcomes
The primary end point was investigator-assessed PFS in the first-line setting per RECIST, version 1.0. Secondary end points included overall survival (OS) in the first-line setting, PFS in the second-line setting per RECIST, version 1.0, and overall response (complete or partial response) and clinical benefit (complete or partial response, or stable disease, each lasting ≥24 weeks) in both settings per RECIST, version 1.0. Definitions of PFS and OS are given in the eMethods in the Supplement. Safety, assessed by the frequency of adverse events graded per National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0, 14 was determined in both settings.
Statistical Analysis
First-line and second-line efficacy were analyzed in all patients assigned to first-line treatment (full analysis set) and all patients who received at least 1 dose of second-line treatment. Median PFS and median OS were estimated using the Kaplan-Meier method and presented with exact 95% CIs. Interquartile ranges (IQRs) were defined as 25th to 75th percentiles.
If the disease did not progress or the patient did not die by the analysis cutoff date, or if a patient received any further antineoplastic therapy (including the per-protocol secondline treatment for the analysis of the first-line data), PFS was censored at the time of the last tumor assessment. Overall survival was censored at the date of last contact if a death was not observed by the data cutoff. The proportion of patients with an overall response and clinical benefit are presented with exact 95% CIs based on the Clopper-Pearson method. Safety was reported for all patients who received at least 1 dose of study medication and at least 1 postbaseline safety assessment.
Sample size was calculated based on an estimated median PFS with reasonable accuracy (width of 95% CI) for firstline treatment with everolimus plus letrozole. It was estimated that, with 200 patients enrolled, considering a recruitment period of 18 months and 1 year of follow-up, expected 95% CIs for median PFS at 11, 12, 13, and 14 months (with 10% lost to follow-up) were 9. respectively. SAS, version 9.4 (SAS Institute Inc) was used in data analysis.
Results
Between March 7, 2013 and December 17, 2014, 245 patients were screened for eligibility, 202 of whom were enrolled and provided with first-line treatment with everolimus and letrozole (Figure 1 ). In the first-line setting, median age was 64.0 years (IQR, (IQR, weeks) and 75.1 weeks (IQR, 21.9-112.3 weeks), respectively; median actual dose intensity of everolimus was 8.5 mg/d (IQR, 6.0-9.9 mg/d). Following disease progression in the first-line setting, 50 (24.8%) patients received second-line treatment with everolimus plus exemestane at the investigator's discretion. In the second-line setting, median patient age was 62.0 years (IQR, 57.0-66.0 years) Figure 2 ). Median PFS determined without censoring patients who initiated new anticancer therapies was 20.9 months (95% CI, 17.9-24.0 months). Overall response and clinical benefit rates were 45.0% (95% CI, 38.1%-52.2%) and 74.3% (95% CI, 67.7%-80.1%), respectively. The majority of patients had a reduction in tumor size from baseline with everolimus plus letrozole (eFigure in the Supplement). Median OS in patients receiving everolimus plus letrozole was not reached (95% CI, 37.0-not estimable) (Table 2; Figure 3 ). Fifty (24.8%) deaths overall had been reported and data from 152 (75.2%) patients had been censored. The estimated OS rate at 24 months was 78.7% (95% CI, 72.1%-83.9%).
In the second-line setting, 31 PFS events were reported. Median PFS was 3.7 months (95% CI, 1.9-7.4 months) with everolimus and exemestane (Table 1; Figure 2 ). Overall response and clinical benefit rates were 6.0% (95% CI, 1.3%-16.5%) and 28.0% (95% CI, 16.2%-42.5%), respectively.
In . Serious adverse events occurred in 62 (30.7%) patients, were suspected to be drug related in 24 (11.9%) patients, and were mostly grade 3 to 4 in severity (eTable 6 in the Supplement). Pneumonia was the most common (any grade) serious adverse event regardless of causality (9 [4.5%] patients) and was suspected to be drug related in 5 (2.4%) patients. Pneumonia was also the most common grade 3 to 4 serious adverse event regardless of causality (6 [3.0%] patients) and suspected to be drug related in 4 (2.0%) patients. Adverse events leading to discontinuation occurred in 51 (25.2%) patients overall and were suspected to be drug related in 43 (21.3%) patients (eTable 7 in the Supplement); stomatitis was the most common adverse event leading to discontinuation regardless of causality (7 [3.5%] patients).
In the second-line setting, 50 patients receiving everolimus plus exemestane were assessed for safety. Everolimus dose reductions and interruptions were required in 9 (18.0%) and 14 (28.0%) patients, respectively (further details provided in eTable 4 in the Supplement). Adverse events (any grade) requiring dose adjustments or interruptions occurred in 14 (28.0%) patients, the most common of which was pneumonitis (3 [6.0%]). The most common adverse events (any grade) occurring in 20% or more of patients, regardless of causality, were stomatitis and decreased weight (10 [20.0%] each) (eTable 5intheSupplement). Similar to the first-line setting, most adverse events were grade 1 to 2 in severity; the most common grade 3 to 4 adverse event was hypertension (5 [10.0%] patients). Stomatitis was the most common all-grade adverse event suspected to be drug related (10 [20.0%] patients). Serious adverse events occurred in 8 (16.0%) patients, were suspected to be drug related in 3 (6.0%) patients, and were mostly grade 3 to 4 in severity (eTable 6 in the Supplement). Adverse events leading to discontinuation occurred in 3 (6.0%) patients, and all were suspected to be drug related (eTable 7 in the Supplement). A total of 50 (24.8%) patients died during the study, most commonly due to study indication (breast cancer, 40 [19.8%] ). Seven (3.5%) patients died within 28 days of completing firstline treatment due to study indication (4 [2.0%]) and septic shock, pyrexia, and pneumonia (1 each [0.5%]). Two (4.0%) patients died within 28 days of completing second-line treatment due to study indication and septic shock (1 each [2.0%]).
Overall, 9 (4.5%) patients experienced serious adverse events (any grade) suspected to be drug related before their deaths (details provided in eResults in the Supplement).
Discussion
Current guidelines recommend offering endocrine therapy as a first-line treatment to patients with HR+, HER2-advanced breast cancer, excluding those with immediately life- The median PFS achieved in this study was particularly impressive given the heavy baseline disease burden of the patient population: 96.0% had metastatic disease, 67.8% had 3 or more metastatic sites, and 60.9% had visceral metastases. A sensitivity analysis, performed without censoring patients who started new anticancer therapies, achieved a median PFS that was similar to the primary analysis. The treatment landscape for HR+, HER2-advanced breast cancer has been evolving in recent years with the licensing of cyclin-dependent kinase inhibitors, after clinical studies demonstrated the benefit of adding palbociclib or ribociclib succinate to endocrine therapy in the first-line setting. 17, 18 Despite these newer treatment options, previously reported preclinical and clinical data show that combinations of mTOR inhibitors and endocrine therapy remain important and effective options. The combination of everolimus and letrozole has demonstrated synergistic activity in preclinical models and in the neoadjuvant breast cancer setting. 5, 6 In the second-line setting, the TAMRAD study also
showed that the addition of everolimus to tamoxifen provided improved efficacy compared with tamoxifen alone, 3 while the PrECOG 0102 study confirmed the clinical benefit of combining everolimus with fulvestrant. 8 The study
reported herein provides further indication that dual inhibition with the mTOR inhibitor everolimus combined with endocrine therapy offers an important option in the management of HR+, HER2-advanced breast cancer. A limited number of studies have investigated mTOR inhibitors combined with endocrine therapy in the first-line setting, and in 1 such study, the combination of temsirolimus and letrozole did not improve PFS or OS in the first-line setting vs letrozole alone. 19 However, caution should be used when comparing these data with BOLERO-4 study data due to differences between the study designs and patient populations (BOLERO-4 was a single-arm, open-label phase 2 study of patients with HER2-disease that had progressed during prior aromatase inhibitor therapy, whereas HORIZON was a phase 3, placebo-controlled study of aromatase inhibitor-naive patients with HER2-or HER2-positive disease that was stopped early due to lack of efficacy) and between the modes of action of the study drugs. Data describing continued treatment with an mTOR inhibitor but combined with a different endocrine therapy partner in patients whose disease has progressed with prior mTOR inhibitors are equally scarce. The BOLERO-4 study also explored continued treatment with everolimus plus exemestane in patients whose disease progressed with everolimus plus letrozole in the first-line setting. Other second-line studies in patients whose disease had not progressed during everolimus therapy have shown that everolimus combined with exemestane or fulvestrant offered median PFS improvements of 4.6 to 5.3 months vs endocrine therapy alone in patients with aromatase inhibitor-resistant breast cancer. 8, 9 Although in our study second-line treatment with everolimus and exemestane showed limited efficacy (median PFS, 3.7 months; 95% CI, 1.9-7.4 months), the treatment was offered only to a select number of patients. In addition, the results should be interpreted with caution due to the small sample size, b Recorded on the end-of-treatment case report form, study evaluation completion case report form, or defined as not adequately followed up as the data cutoff.
pretreatment with or prior exposure to everolimus in the firstline setting, the relatively advanced disease present among the patients, the potential similar mechanisms of letrozole and exemestane, and differences in study design.
No new safety signals were observed in either setting of this study. Overall safety was generally manageable, consistent with the known safety profile of everolimus, and incidences of on-treatment death due to pneumonia or septic shock were consistent with the BOLERO-2 study.
3 Everolimus dose reductions and interruptions were relatively high in the firstline setting, and most were due to adverse events. However, most adverse events were grade 1 to 2 in severity, and grade 3 to 4 adverse events were relatively uncommon. Higher rates of stomatitis were noted in the first-line setting compared with the second-line setting, reflective of the rapid onset associated with everolimus-related stomatitis. 20 Overall safety was better in the second-line setting and likely reflects the selection of patients for continued treatment based on their tolerability of everolimus in the first-line setting.
Limitations
Although the results from this study are impressive, crosstrial comparisons should be made with caution due to the single-arm, open-label, phase 2, nonrandomized design of this BOLERO-4 study.
Conclusions
The PFS benefit demonstrated by everolimus plus letrozole was within range of that observed with combinations of aromatase inhibitors and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in the advanced breast cancer setting, despite the heavy disease burden among the postmenopausal ER+, HER2-advanced breast cancer patient population. While combinations of aromatase inhibitors and CDK4/6 inhibitors are already a preferred first-line option in many countries, these combinations have not yet shown that they can provide an additional OS benefit vs aromatase inhibitors alone and are not universally accessible due to their high cost. The PFS benefit demonstrated by everolimus plus letrozole in this study also exceeded that observed with letrozole alone in previous phase 3 studies of postmenopausal women with HR+ advanced breast cancer (median PFS, 9.0-9.4 months). 19, 21 There may therefore still be a place for everolimus in the advanced breast cancer treatment landscape, and our hypothesis that the combination of everolimus and letrozole can enhance the effectiveness of endocrine therapy in the first-line setting and delay or potentially prevent the development of endocrine resistance remains an interesting concept. Following the arrival of CDK4/6 inhibitors, there is also interest in determining the optimal sequence of therapies. Despite the challenges posed by the patient population, our findings are insightful and provide data describing everolimus in areas of the advanced breast cancer landscape where existing data are scarce. Furthermore, with new and emerging phosphatidylinositol 3-kinase inhibitors receiving significant attention, there is sufficient evidence to suggest that the phosphatidylinositol 3-kinase/mTOR pathway remains important and warrants further exploration in the treatment of HR+, HER2-advanced breast cancer. Role of the Funder/Sponsor: The study was designed, conducted, and analyzed by the funder in conjunction with the investigators and study steering committee. The funder provided the study drugs. The authors confirm adherence to the study protocol and vouch for the accuracy and completeness of the data. Dr Royce also had access to the study data, was involved in their interpretation and analysis, and had final responsibility for the decision to submit for publication.
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eMethods. Further Methodology Further Patient Inclusion/Exclusion Criteria
Fasting serum cholesterol and triglycerides levels could be no more than 300 mg/dL and 2.5 × upper limit of normal, respectively. Prior neoadjuvant or adjuvant endocrine therapy was permitted; therapy with nonsteroidal aromatase inhibitors must have been completed at least 1 year before enrolment.
Patients were excluded if they had prior hormonal or other systemic therapies for advanced disease, prior treatment with (or known hypersensitivity to) a mammalian target of rapamycin inhibitor, chronic treatment with systemic immunosuppressants, strong inhibitors or inducers of the isoenzyme cytochrome P450 3A within 5 days of enrolment, or radiotherapy within 4 weeks of the first study dose (except localized analgesic radiotherapy for lytic lesions at risk of fracture no more than 2 weeks before enrolment). Patients with only nonmeasurable lesions other than bone metastasis, with another prior malignancy within 5 years (except adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma, or nonmelanomatous skin cancer), or a history of central nervous system metastasis, were also excluded, as were patients receiving hormone replacement therapy at enrolment, or with a known history of human immunodeficiency virus seropositivity, symptomatic deterioration of lung function, severe and/or uncontrolled medical condition (including diabetes), bilateral diffuse lymphangitis, or active bleeding diathesis.
Procedures -Definition of Dose Modifications
If treatment was interrupted due to toxicity, it could only be resumed after recovery to grade 1 or less; however, if treatment was interrupted for 28 days or more, the patient was required to discontinue the study.
Study drug reintroduction occurred at the initial dose, or a lower dose based on toxicity type and severity; everolimus dose reduction to 5 mg, daily or every other day, was permitted.
Procedures -Stomatitis Substudy
In the USA, where alcohol free dexamethasone mouthwash was commercially available, 24 patients with confirmed stomatitis on treatment entered an exploratory, randomized substudy, which assessed 0.5 mg/5 mL alcohol free dexamethasone mouthwash versus the local standard of oral care for the treatment of symptomatic stomatitis. Additional outcomes assessed were time to first stomatitis occurrence (calculated using patient reported dates) and duration of first stomatitis occurrence (estimated using patient reported and investigator reported dates).
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In addition, all 139 patients with confirmed stomatitis on treatment were instructed to complete an Oral Stomatitis Daily Questionnaire, which assessed overall health, mouth and throat soreness, mouth pain severity, and effect on daily activities. These results have been presented previously (Villanueva C, Tsugawa K, 
Outcomes Definitions of Progression free Survival and Overall Survival
Progression free survival in the first line setting was defined as the time from enrolment to first documented progression or death from any cause. Overall survival in the first line setting was defined as time from enrolment to death from any cause; estimated 24 months after the last patient first visit. Progression free survival in the second line setting was defined as time from start of second line treatment to documented disease progression or death from any cause.
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eResults. Adverse Events Serious Adverse Events Suspected to be Drug Related Prior to Their Deaths Occurring During the Study
In the first line setting, a total of eight patients experienced serious adverse events suspected to be drug related prior to the deaths occurring during the study. One patient had hypokalemia; one patient had diarrhea and kidney failure; one patient had dyspnea; one patient had phlebitis; one patient had septicemia with organ failure, and streptococcal infection; one patient had hyponatremia and anemia; one patient had pneumonia and respiratory failure; and one patient had two cases of pneumonia, shortness of breath, and rule out sepsis.
In the second line setting, one patient experienced dyspnea and renal failure.
eFigure. Target Lesion Change With Everolimus Plus Letrozole in the First Line Setting, Per Local Investigator Review (Full Analysis Set)
a Patients who had a best percentage change from baseline more than 0% but had an overall response of progressive disease due to a new lesion.
Decrease in best percentage change from baseline: 69%.
Increase/zero change in best percentage change from baseline: 50%.
Percentage change in target lesion contradicted by overall lesion response = progressive disease: 26%.
